LY3537982

Eli Lilly and Company · Phase 3 active Small molecule

LY3537982 is a GLP-1 receptor agonist Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Type 2 diabetes mellitus, Obesity or weight management. Also known as: Olomorasib.

LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.

LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

• Baseline phase 3 → approval rate +58.3pp
  Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
• Big-pharma sponsor +3.0pp
  Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LY3537982
Also known as	Olomorasib
Sponsor	Eli Lilly and Company
Drug class	GLP-1 receptor agonist
Target	GLP-1R
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3537982 is being developed as a next-generation GLP-1 agonist, potentially with improved pharmacokinetic properties or dual/triple agonist activity targeting GLP-1 and other metabolic receptors.

Approved indications

• Type 2 diabetes mellitus
• Obesity or weight management

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

Key clinical trials

• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (PHASE3)
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (PHASE3)
• A Study of Olomorasib (LY3537982) in Healthy Participants (PHASE1)
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (PHASE1, PHASE2)
• A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (PHASE1)
• A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (PHASE1)
• A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (PHASE1)
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LY3537982 CI brief — competitive landscape report
• LY3537982 updates RSS · CI watch RSS
• Eli Lilly and Company portfolio CI

Frequently asked questions about LY3537982

What is LY3537982?

LY3537982 is a GLP-1 receptor agonist drug developed by Eli Lilly and Company, indicated for Type 2 diabetes mellitus, Obesity or weight management.

How does LY3537982 work?

LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.

What is LY3537982 used for?

LY3537982 is indicated for Type 2 diabetes mellitus, Obesity or weight management.

Who makes LY3537982?

LY3537982 is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is LY3537982 also known as anything else?

LY3537982 is also known as Olomorasib.

What drug class is LY3537982 in?

LY3537982 belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is LY3537982 in?

LY3537982 is in Phase 3.

What are the side effects of LY3537982?

Common side effects of LY3537982 include Nausea, Vomiting, Diarrhea, Constipation, Abdominal pain.

What does LY3537982 target?

LY3537982 targets GLP-1R and is a GLP-1 receptor agonist.

Related

• Drug class: All GLP-1 receptor agonist drugs
• Target: All drugs targeting GLP-1R
• Manufacturer: Eli Lilly and Company — full pipeline
• Therapeutic area: All drugs in Diabetes
• Indication: Drugs for Type 2 diabetes mellitus
• Indication: Drugs for Obesity or weight management
• Also known as: Olomorasib